Background and objectives: Obstructive sleep apnea-hypopnea syndrome (OSAHS) and chronic obstructive pulmonary disease (COPD) are independently linked to an increase in cardiovascular disease (CVD). Only a few studies have been published linking the association between overlap syndrome and congestive heart failure (CHF). This review highlights the interplay between overlap syndrome (OSAHS-COPD) and CHF. Materials and methods: We thoroughly reviewed published literature from 2005 to 2022 in PubMed, Google Scholar, and Cochrane databases to explore the link between overlap syndrome and cardiovascular outcomes, specifically congestive heart failure. Results: Research indicates that individuals with overlap syndrome are more likely to develop congestive heart failure than those with COPD or OSA alone. Congestive heart failure is a common comorbidity of overlap syndrome, and it has a two-way connection with sleep-related breathing disorders, which tend to occur together more frequently than expected by chance. Conclusions: CHF seems to have a strong relationship with OS. Further research is required to understand the relationship between OS and CHF.
Primary pulmonary hypertension (PPH), now known as pulmonary arterial hypertension (PAH), has envisioned significant treatment breakthroughs in the past decade. Treatment has focused on improving patient survival and quality of life and delaying disease progression. Current therapies are categorized based on targeting different pathways known to contribute to PAH, including endothelin receptor antagonists (ERAs), phosphodiesterase-5 inhibitors (PDE-5 inhibitors), prostacyclin analogs, soluble guanylate cyclase stimulators, activin signaling inhibitors as Sotatercept. The latest addition to treatment options is soluble guanylate cyclase stimulators, such as Riociguat, which directly stimulates the nitric oxide pathway, facilitating vasodilation. Looking to the future, advancements in PAH treatment focus on precision medicine involving the sub-stratification of patients through a deep characterization of altered Transforming Growth Factor- β(TGF-β) signaling and molecular therapies. Gene therapy, targeting specific genetic mutations linked to PAH, and cell-based therapies, such as mesenchymal stem cells, are under investigation. Novel pharmacologic targets are also developing, including growth factors and inflammation-modulating pathways. Ongoing clinical trials aim to refine these emerging treatments and better understand their long-term benefits and safety profiles. This review will discuss the current therapies that help delay the progression and improve survival and future PAH treatments that hold potential for curative approaches targeting underlying disease mechanisms.
Pulmonary hypertension is a progressive and potentially fatal medical condition. Around 1% of global population is estimated to be affected by it. With significant advancement in diagnostic and therapeutic modalities in pulmonary hypertension, there has been a surge in interest in medical fraternity. We aim to revisit some of the major historical events pertinent to the evolution of the field of pulmonary hypertension. We try to understand how our predecessors in medicine laid foundation based on which the field of pulmonary hypertension is growing.
Spindle cell carcinoma (SpCC), also referred to as sarcomatoid carcinoma, makes up less than 3% of all head and neck squamous cell carcinomas (SCCs). It is an uncommon and unusual biphasic malignant tumor primarily affecting the upper aero-digestive tract. SpCC consists of spindled or pleomorphic tumor cells. Mostly, these tumors are seen in the fifth or sixth decades of life and are strongly associated with smoking and alcohol. We hereby report an infrequently encountered case of SpCC in a patient with xeroderma pigmentosum (XP), who was young, nonsmoker, and did not consume alcohol. The mass arose from the right orbit and involved the entire right face. The postoperative histopathological report showed SpCC. Surgical excision of the mass was performed. We aimed to add to the prevailing literature by reporting this case. J Med Cases. 2023;14(6):191-195 doi: https://doi.org/10.14740/jmc4110